Oragenics OGEN
NYSE OGEN
$0.34 +0.00 (+0.00%)
As of: Nov 11, 2026 · 9:46 AM EST

Oragenics (OGEN) Gains from Sales and Divestitures (2009 - 2023)

Updated

Oragenics' Gains from Sales and Divestitures was -$52,399 in Q4 2023.

Analysis

Oragenics (OGEN) Gains from Sales and Divestitures (2009 - 2023) Analysis & Trends

For FY2023, Gains from Sales and Divestitures at Oragenics came in at -$29,956.

  • In earlier years, Gains from Sales and Divestitures was $10,964 in FY2022.
  • The Q4 2023 figure marks the highest quarterly Gains from Sales and Divestitures since Q1 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Oragenics 1.58 Mn -28.20 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 -52,399.00
Mar 31, 2022 10,964.00
Mar 31, 2017 -121.00
Jun 30, 2016 1.45 Mn
Dec 31, 2009 -11,469.00
API Access

Oragenics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=OGEN&period=max&api_key=YOUR_API_KEY